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Abstract
Objective: To study patterns of oral tranexamic acid use among pre- and perimenopausal Danish 
women following the introduction of the levonorgestrel-releasing intrauterine system.
Study design: We conducted a nationwide descriptive drug utilization study including all 15-54-year-
old Danish women during the period 1996-2017. National health registers provided information on use 
of oral tranexamic acid, the levonorgestrel-releasing intrauterine system, other hormonal 
contraceptives, and cyclical oral progestogens as well as incidence rates of endometrial ablations and 
hysterectomies. Linear calendar time trends in usage of these treatments were tested using Poisson 
and logistic regression models, which adjusted for user age and provided p-values for significance. 
Results: During the study period, use of the levonorgestrel-releasing intrauterine system increased 
14-fold among women aged 15-54 years, from 2.3 in 1996 to 32 users per 1,000 person-years in 2017 
(p<0.001). The increase happened consistently throughout the study period for women aged 20-54 
years, but not for the youngest age group, 15-19 years, among whom the increase only happened in 
the end of study period following the introduction of a levonorgestrel-releasing intrauterine system with 
a smaller frame. 
Use of oral tranexamic acid declined from 11.3 in 1996 to 6.3 per 1,000 person-years in 2017 among 
women aged 20-54 years (p<0.001) but increased from 1.4 to 1.9 users per 1,000 person-years 
among those aged 15-19 years (p<0.001). 
Use of other hormonal contraceptives remained stable over time at around 300 users per 1,000 
person-years, while the use of cyclical oral progestogens decreased from 4 to 0.1 users per 1,000 
person-years (p<0.001). The incidence of hysterectomies decreased from 3.1 to 2.1 per 1,000 person-
years (p<0.001), while the incidence rate of endometrial ablations increased from 0.7 to 1.3 per 1,000 
person-years (p<0.001). 
Conclusions: In Denmark, increasing use of the levonorgestrel-releasing intrauterine system has 
been accompanied by a decrease in use of oral tranexamic acid, cyclical oral progestogens, and 
hysterectomy.
Keywords: Endometrial ablation, heavy menstrual bleeding, hormonal contraception, hysterectomy, 
levonorgestrel-releasing intrauterine system, tranexamic acid
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Implication
Increasing use of the levonorgestrel-releasing intrauterine system was accompanied by declining use 
of other therapies used to decrease menstrual bleeding. The non-contraceptive benefits of hormonal 
contraception should be considered in cost-effectiveness analyses.
4
1. Introduction
Hormonal contraceptive methods are recognized as effective treatment options for heavy menstrual 
bleeding.[1 2 3] Containing progestins/progesterone, hormonal contraceptives inhibit normal 
proliferative changes in the endometrium, causing endometrial atrophy and thereby reduction in 
menstrual blood loss.[4] Compared to combined oral contraceptives, the levonorgestrel-releasing 
intrauterine system has shown to be associated with a greater reduction in heavy menstrual bleeding 
and a larger improvement of quality of life.[2]
The levonorgestrel-releasing intrauterine system has also shown to be superior in the treatment of 
heavy menstrual bleeding compared to other non-contraceptive medical therapies, such as oral 
tranexamic acid. [2] Tranexamic acid is an anti-fibrinolytic agent given to people experiencing heavy 
bleeding. By reversibly binding to plasminogen, tranexamic acid prevents the binding and lysis of 
fibrin, thereby preserving fibrin’s haemostatic structure. [5] Since the release of tranexamic acid in the 
1960s, the orally administrated version of the drug has been prescribed to women with heavy 
menstrual bleeding. [6 7] 
In Denmark, oral tranexamic acid is mostly used by women of reproductive age, with heavy menstrual 
bleeding as the main indication for this treatment. [8] Thus, changes in patterns of oral tranexamic acid 
utilization among Danish women could potentially have occurred following the introduction of the 
levonorgestrel-releasing intrauterine system to the Danish market in the year 1990. Furthermore, in 
2013, a smaller sized levonorgestrel-releasing intrauterine system was introduced to the market, also 
potentially changing use of oral tranexamic acid. 
We aimed to describe the use of oral tranexamic acid among Danish women aged 15-54 years 
following the introduction of the levonorgestrel-releasing intrauterine system in Denmark. To further 
explore the link between the use of these two drugs, we also assessed use of other medical and 
surgical therapies for heavy menstrual bleeding. 
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2. Material and methods
2.1 Study population
Using information on birth, migration, and death provided by The Danish Civil Registration System and 
The National Danish Register of Causes of Death, we identified all person-years contributed by 15-54-
year-old women alive and living in Denmark during the period 1996-2017. [9 10]
2.2 Outcomes of interest
In Denmark, all redeemed prescriptions are registered in the Danish National Register of Medicinal 
Product Statistics (“prescription register”). [11] The register holds information on expedition date, 
number of purchased packages, size of each package, as well as type and size of the drug unit of all 
redeemed prescription since the year 1995. [11]
2.2.1 The levonorgestrel-releasing intrauterine system
Information on exposure to the levonorgestrel-releasing intrauterine system in the study population 
was provided by searching the Anatomical Therapeutic Chemical code of the levonorgestrel-releasing 
intrauterine system (ATC code G02BA03) in the prescription register.[11] Use of levonorgestrel-
releasing intrauterine system was assessed as user rates according to five-year age groups and/or 
calendar time. 
User rates of the levonorgestrel-releasing intrauterine system were calculated as number of women 
who redeemed at least one prescription of the levonorgestrel-releasing intrauterine system in a given 
calendar year and/or age group and reported per 1,000 person-years. 
2.2.2 Oral tranexamic acid
Information on exposure to oral tranexamic acid in the study population was also provided by the 
prescription register (ATC code B02AA02), the assessment restricted to tablets only. Use of oral 
tranexamic acid was assessed according to five-year age groups and/or calendar time. The 
assessment included user rates as well as total and median number of prescriptions and dose 
redeemed. 
User rates of oral tranexamic acid were calculated as number of women who redeemed at least one 
prescription of oral tranexamic acid in a given calendar year and/or age group and reported per 1,000 
person-years. A sub-assessment of annual user rates was made for only first-time users, defined as 
women who, prior to the year in which they were included as users, did not redeem any prescription of 
oral tranexamic acid.  
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Doses were reported in grams.  From April 2004, a dosage variable was added to the prescription 
register, making it possible to extract information on dosage regimen prescribed. [11] However, due to 
inconsistent reporting, dosage information was only available for 67 % of redeemed prescriptions of 
oral tranexamic acid, 80 % of these with a dosage regimen of 1 gram x 3 daily for five days. Thus, 15 
grams of oral tranexamic acid was considered to cover the treatment of one menstrual cycle. 
2.2.3 Other treatments for heavy menstrual bleeding
The prescription register also provided information on use of other hormonal contraceptives (G03AA, 
G03AB, G03AC, G02BB01, G03HB01), cyclical oral progestogens (G03DA02, G03DB08), and 
ulipristal acetate (G03XB02). We excluded use of cyclical oral progestogens, if it was used as 
hormonal therapy/hormonal replacement therapy (G03C, G03F). 
By searching relevant procedural codes (codes of the Nordic Medico-Statistical Committee 
Classification of Surgical Procedures) in The Danish National Patient Register, we achieved 
information on endometrial ablation (KLCA16, KLCB28, KLCB32), hysterectomy (KLCC10, KLCC11, 
KLCC20, KLCD), myomectomy (KLCB10, KLCB11, KLCB20), and uterine fibroid embolization 
(KPDT40), experienced by the study population. [12]
Use of these drugs and surgical procedures was assessed according to calendar time and five-year 
age groups. The assessment included user rates, which were calculated as number of women who 
redeemed at least one prescription of the respective drugs/experienced the respective surgical 
procedures in a given calendar year and age group and reported per 1,000 person-years. 
Furthermore, among oral-tranexamic acid users, we calculated the proportion of women, who became 
users of these other therapies or the levonorgestrel-releasing intrauterine system within twelve months 
from first prescription of oral tranexamic acid. 
2.3 Statistical analyses
Linear calendar time trends in user rates were tested using Poisson regression, while linear calendar 
time trends in binary outcomes of interest were tested using logistic regression. The regression 
models included an age group variable to test if the linear calendar time trends were independent of 
the annual distribution of age in the study population. The level of statistical significance was set at 
5%. Data were analysed using SAS, version 9.4 (SAS Institute).
2.4 Ethics Approval
The study was approved by the Danish Data Protection Agency and the Danish Health Data Board. 




3.1 Use of the levonorgestrel-releasing intrauterine system and oral tranexamic acid by the study 
population
During the 22-year-long study period, 278,334 Danish women aged 15-54 years bought 368,849 
levonorgestrel-releasing intrauterine systems.  
The annual user rate of levonorgestrel-releasing intrauterine system increased 14-fold during the 
study period, from 2.3 to 32 users per 1,000 person-years (p<0.001, figure 1). Use of the 
levonorgestrel-releasing intrauterine system increased consistently in all age groups, except in the 
youngest age group (15-19-year-olds), where the increase happened abruptly after the year 2013 
(figure 2). Throughout the entire study period, usage peaked among women aged 35-44 years and 
was lowest among the youngest (15-19 years) and oldest (50-54 years) age group.   
Oral tranexamic acid was used by 152,878 15-54-year-old Danish women, who redeemed a total of 
388,969 prescriptions from 1996 to 2017. In all years studied, the median of redeemed oral 
tranexamic acid was 1 prescription of 15 grams, accounting for the treatment of one menstrual cycle. 
Use according to five-year age groups are shown in supplementary table 1. During the study period, 
Danish hospitals used 14.9 % of oral tranexamic acid for inpatients. This tranexamic acid was not 
included in this study due to it not being registered on an individual level in the prescription register. [8]
Among the entire study population, the annual user rate of oral tranexamic acid declined throughout 
the study period from 10.1 to 5.7 users per 1,000 person-years (43.6 % decline, p <0.001, figure 1). A 
sub-assessment of only first-time users showed a similar decline by time (p <0.001, supplementary 
figure 1). Figure 3 illustrates time trends according to five-year age groups. For all included age 
groups above the age of 19, the annual user rate of oral tranexamic acid decreased by time (p=0.024 
for age group 20-24 years; p<0.001 for the rest). The decline in annual users from 1996 to 2017 
ranged from 23.6 % in women aged 20-24 years to 50.0 % in 35-44-year-old women. In 15-19-year-
old women, however, the annual user rate increased by 40.1 % from 1996 to 2017 (p <0.001). 
Figure 4 illustrates the almost linear correlation between annual user rate of oral tranexamic acid and 
the annual user rate of the levonorgestrel-releasing intrauterine system, the slope of the correlation 
suggesting a decline of one user of oral tranexamic acid for every 6.5 additional users of the 
levonorgestrel-releasing intrauterine system. 
3.2 Use of other treatments for heavy menstrual bleeding among the study population
No time trend was observed for the use of other hormonal contraceptives (annual user rate of around 
300 users per 1,000 person-years). 
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The annual user rate of cyclical oral progestogens declined from 4 in 1996 to 0.1 users per 1,000 
person-years in 2017 (p<0.001).  
The annual incidence rate of endometrial ablations increased from 0.7 to 1.3 per 1,000 person-years 
(p<0.001), while the incidence rate of hysterectomies decreased throughout the study period from 3.1 
to 2.1 hysterectomies per 1,000 person-years (p<0.001).  
Supplementary figure 2-5 show the time trends according to five-year age groups. 
Time trends in use of uterine fibroid-specific treatments are shown in supplementary figure 6. These 
treatments were rarely used throughout the study period, the average annual incidence rate being 
0.24 per 1,000 person-years.  
3.3 Treatments among users of oral tranexamic acid
Of the 152,878 women redeeming at least one prescription of oral tranexamic acid during 1996-2017, 
148,027 (97 %) could be followed for one year from first prescription of oral tranexamic acid (all 
women included, except those being first-time users in 2017). Of these, only 54,717 (40.0%) either 
redeemed a prescription of the levonorgestrel-releasing intrauterine system, another hormonal 
contraceptive, or cyclical oral progestogens or experienced an endometrial ablation or hysterectomy 
within the first year after their first redemption of an oral tranexamic acid prescription. The proportion 
of women receiving one of these treatments within a year from their first prescription of oral 
tranexamic acid increased from 29.9 % in 1996 to 40.9 % in 2016 (p<0.001).  Table 1 shows use of 
these treatment options within twelve months after first prescription of oral tranexamic acid according 
to calendar time. Use of the levonorgestrel-releasing intrauterine system within twelve months from 
first usage of oral tranexamic acid increased significantly over time (p<0.001). Same did the proportion 
of women getting an endometrial ablation (p<0.001). Use of cyclical oral progestogens declined over 
time (p<0.001), while use of other hormonal contraceptives and hysterectomies did not change 
considerably or systematically throughout the period. Treatments received within a year from first 
prescription of oral tranexamic acid are shown according to five-year age groups in supplementary 
table 2. Use of the levonorgestrel-releasing intrauterine system peaked in the 35-49-year-olds, 
whereas use of other hormonal contraceptives within a year from oral tranexamic acid usage peaked 
in the youngest age group.   
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4. Discussion
This nationwide study shows as use of the levonorgestrel-releasing intrauterine system increased 14-
fold among Danish women aged 15-54 years over the past two decades, a clinically and statistically 
significant decline occurred in use of oral tranexamic acid among the 20-54-year-olds. In addition, rate 
of hysterectomies decreased throughout the study period, confirming prior reports on the ability of the 
levonorgestrel-releasing intrauterine system to significantly reduce menstrual blood loss. [2]  
The levonorgestrel-releasing intrauterine system is known to both effectively treat heavy menstrual 
bleeding and to reduce the risk of development of heavy menstrual bleeding in women using it for 
contraceptive purposes. [2] Furthermore, the levonorgestrel-releasing intrauterine system has shown 
to be superior in reducing heavy menstrual bleeding and in reducing the effect of heavy menstrual 
bleeding on quality of life compared to other medical therapies, including oral tranexamic acid. [2, 13] 
Thus, the 14-fold increase in use of the levonorgestrel-releasing intrauterine system observed 
throughout the study period could explain the observed decline of both repeat-users and first-time-
users of oral tranexamic acid, although we recognize that other factors may have influenced the 
change in oral tranexamic acid utilization. 
In this study, use of the levonorgestrel-releasing intrauterine system among 15-19-year-olds did not 
increase significantly until after 2013, when a smaller intrauterine system was introduced to the Danish 
market for nulliparous. Although increasing, the user rate of the levonorgestrel-releasing intrauterine 
system in the age group 15-19 years was the lowest of all age groups. We interpret these findings as 
indications of hesitance of using the intrauterine system in young females, and we believe that this 
hesitance could explain, why we do not see a decline in oral tranexamic acid usage among females 
aged 15-19 years.  
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Table 1:  
Treatments for heavy menstrual bleeding within twelve months after first prescription of oral 



















  (% of n)
1996 13,976 2.6 15.4 4.5 2.3 7.2
1997 10,046 2.4 16.7 4.7 3.1 6.6
1998 8,911 2.9 16.8 4.5 3.1 6.6
1999 8,545 3.5 18.5 4.1 2.8 6.6
2000 7,335 4.6 18.1 3.8 3.4 6.9
2001 7,360 5.6 19.0 3.8 3.0 7.1
2002 7,709 5.9 20.9 3.9 3.4 6.9
2003 7,190 6.1 20.1 3.6 4.1 6.9
2004 7,178 6.9 20.8 4.0 4.4 6.6
2005 6,711 8.0 21.2 3.3 4.6 6.0
2006 6,685 8.4 21.8 3.3 4.6 6.5
2007 6,581 8.9 20.6 3.1 4.4 6.2
2008 6,204 9.6 21.3 2.6 4.8 6.7
2009 6,092 9.7 21.9 2.1 5.3 7.1
2010 5,952 10.3 22.7 2.2 5.2 6.7
2011 5,790 10.4 22.8 1.9 5.4 6.7
2012 5,519 11.0 21.6 1.8 6.1 6.5
2013 5,470 10.8 20.3 1.4 6.1 6.9
2014 4,962 10.1 20.1 0.9 6.7 7.0
2015 4,830 11.7 20.1 0.6 6.3 6.1
2016 4,981 11.8 20.5 0.4 6.4 6.6




Rates* of the levonorgestrel-releasing intrauterine system, oral tranexamic acid, and cyclical 
oral progestogens as well as incidence rates of hysterectomies and endometrial ablations 
among women aged 15-54 years during the period 1996-2017.
* calculated as number of women who redeemed at least one prescription of the respective drugs in a given 
calendar year per 1,000 person-years. 
Annual rate of other hormonal contraceptives was rather stable throughout the study period, around 300 per 
1,000 person-years. 
Figure 2: 
Rates* of the levonorgestrel-releasing intrauterine system according to five-year age groups 
during the period 1996-2017.
* calculated as number of women who redeemed at least one prescription of the levonorgestrel-releasing 
intrauterine system in a given calendar year and age group per 1,000 person-years.
Figure 3: 
Rates* of oral tranexamic acid according to five-year age groups during the period 1996-
2017.
* calculated as number of women who redeemed at least one prescription of oral tranexamic acid in a given 
calendar year and age group per 1,000 person-years.
Figure 4: 
Correlation between annual rates* of oral tranexamic acid and the levonorgestrel-releasing 
intrauterine system among 15-54-year-old women during the period 1996-2017. 
*calculated as number of women who redeemed at least one prescription of the respective drugs in a given 




Use of oral tranexamic acid according to five-year age groups among 15-54-year-old Danish 
women during the period 1996-2017. 
Age Users First-time users Prescriptions Dose 
group n % n % of 
users
n % n per 
user* 
gram % gram per 
user*
15-19 4,729 2.6 - - 8,512 2.0 1 (1-2) 186,481 2.1 15 (15-30)
20-24 7,332 4.0 6,762 92.2 10,702 2.6 1 (1-1) 220,763 2.5 15 (15-30)
 25-29 11,418 6.2 10,408 91.2 16,964 4.2 1 (1-1) 327,654 3.7 15 (15-30)
 30-34 17,266 9.4 15,350 88.9 29,670 7.6 1 (1-2) 584,841 7.1 15 (15-30)
 35-39 24,894 13.5 21,278 85.5 50,359 13.1 1 (1-2) 1,040,816 12.7 15 (15-30)
 40-44 36,606 19.9 30,626 83.7 81,946 21.4 1 (1-2) 1,753,585 21.5 15 (15-45)
 45-49 48,462 26.3 39,252 81.0 114,677 29.7 1 (1-2) 2,499,928 30.3 30 (15-45)
 50-54 33,283 18.1 24,473 73.5 76,139 19.4 1 (1-2) 1,671,866 20.0 30 (15-45)
Total 183,990 100.0 152,878 83.1 388,969 100.0 1 (1-2) 8,285,934 100.0 15 (15-45)
*Median (1st quantile - 3rd quantile)
Supplementary table 2:
Treatments for heavy menstrual bleeding within twelve months after first prescription of oral 



















  (% of n)
15-19 4,488 2.0 68.1 0.2 0.0 0.0
20-24 6,445 3.0 58.8 0.5 0.1 0.1
 25-29 9,990 3.7 44.9 0.7 0.3 0.7
 30-34 14,891 6.0 31.9 0.9 1.5 2.4
 35-39 20,682 8.1 21.5 1.8 3.9 5.4
 40-44 29,821 9.2 13.8 3.2 6.5 9.3
 45-49 38,101 8.3 8.6 5.1 6.2 6.7
 50-54 23,609 4.7 4.7 5.1 4.3 8.2
Total 148,027 6.9 19.6 3.2 4.3 6.7
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Supplementary figure 1: 
Rates* of oral tranexamic acid according to prior experience with oral tranexamic acid during 
the period 1996-2017.
*calculated as number of women who redeemed at least one prescription of oral tranexamic acid in a given 
calendar year per 1,000 person-years. A woman was defined as a first-time user at time of her first redemption 
of a prescription of oral-tranexamic acid. 
Supplementary figure 2: 
Rates* of other hormonal contraceptives according to five-year age groups during the period 
1996-2017.
*calculated as number of women who redeemed at least one prescription of a hormonal contraceptive other than 
the levonorgestrel-releasing intrauterine system in a given calendar year and age group per 1,000 person-years.
Supplementary figure 3:
Rates* of cyclical oral progestogens according to five-year age groups during the period 
1996-2017.
*calculated as number of women who redeemed at least one prescription of cyclical oral progestogens (without 
prior or simultaneous redemption of estrogens) in a given calendar year and age group per 1,000 person-years.
Supplementary figure 4:
The annual incidence rate of women having an endometrial ablation according to five-year 
age groups during the period 1996-2017.
Supplementary figure 5:
The incidence rate of women having a hysterectomy according to five-year age groups during 
the period 1996-2017.
Supplementary figure 6:
The annual incidence rate of a) women having a myomectomy, b) uterine fibroid embolization, 
and the annual rate* of c) ulipristal acetate in women aged 15-54 years during the period 
1996-2017.
*calculated as number of women who redeemed at least one prescription of ulipristal 
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